Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.20    -0.31 (-12.35%)
Bid:
2.00
Ask:
2.50
Spread: 0.50 (25.00%)
Market Cap: £4.01m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Joint Development Agreement

28 Apr 2025 10:48

RNS Number : 4391G
Nanoco Group PLC
28 April 2025
 

FOR IMMEDIATE RELEASE 28 April 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS THE SAME HAS BEEN RETAINED IN UK LAW AS AMENDED BY THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR").

Nanoco Group PLC

("Nanoco, the "Group", or the "Company")

 

Joint Development Agreement with new second Asian customer

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, is pleased to announce it has signed a major new Joint Development Agreement ("JDA") with a new second Asian chemical customer.

The target of the one-year programme is to optimise lead-free nanomaterials to be incorporated into global electronics applications. Once successful, the subsequent stage will involve scale up to industrial production levels during 2027.

The revenue from the JDA will help the Group exceed current expectations for non-license fee income in FY25, and contribute further revenue to FY26.

Dmitry Shashkov, Nanoco's CEO, commented:

"This JDA with another Asian chemical company highlights the growing focus on the incorporation of quantum dots into sensors for high volume commercial applications.

"The consensus of market research is that quantum dot enabled silicon sensors, especially ones which are lead-free, will disrupt the global consumer electronics market, and Nanoco along with its customers are at the forefront of this technology, and we also have significant IP protections in this area.

"Discussions are ongoing with other potential new customers around further potential projects and we look forward to updating shareholders further in due course."

 

- Ends -

MAR

The information contained within this announcement is considered by the Company to contain inside information for the purposes of UK MAR. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

The person responsible for arranging for the release of this announcement on behalf of Nanoco is Liam Gray, Chief Financial Officer.

Nanoco Group plc:

Dmitry Shashkov, CEO +44 (0)1928 761 404

 

Liam Gray, CFO & Company Secretary

 

Sodali & Co (Public Relations)

Elly Williamson +44 (0)79 3535 1934

Pete Lambie

Nanoco@sodali.com

 

Cavendish Capital Markets Limited (Financial Adviser and Corporate Broker):

Ed Frisby / George Lawson (Corporate Finance) +44 (0) 20 7220 0500

Tim Redfern / Charlie Combe (Corporate Broking)

Jasper Berry (Sales)

 

CDX Advisors (Financial Adviser):

Steven Foland +1 415 425 2224

Steve Month

Patrick Foley 

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium free quantum dots (CFQD® materials) and other patented nanomaterials for use in the electronics industries. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside its existing scaled up production facilities for commercial orders.

Nanomaterials are materials with dimensions typically in the range 1 - 100 nm. Nanomaterials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nanomaterial that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE® quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectra, rendering them useful for applications including cameras and image sensors.

Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRSEISUAEISELL
Date   Source Headline
9th Jun 20267:00 amRNSGlass Lewis recommendation
5th Jun 202611:55 amRNSTR-1: Notification of major holdings
27th May 20267:00 amRNSIntention to delist from London Stock Exchange
20th Apr 20265:37 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSInterim Results
13th Apr 20267:00 amRNSNotice of Results
26th Mar 20267:00 amRNSShoei Litigation Conclusion
19th Mar 20267:00 amRNSStay of Shoei Litigation
23rd Feb 20267:00 amRNSShoei Litigation Update
26th Jan 20267:00 amRNSConclusion of CDX process & Directorate changes
15th Jan 20261:08 pmRNSReceipt of Litigation Proceeds
13th Jan 20264:50 pmRNSResult of AGM
12th Jan 20267:00 amRNSLitigation update
9th Dec 20257:00 amRNSBlocklisting Six-Monthly Return
8th Dec 202511:16 amRNSNotice of AGM
27th Nov 20257:00 amRNSResponse to non-infringement claim
26th Nov 20257:00 amRNSAnnual Report and Accounts
20th Nov 20257:00 amRNSLitigation outcome – Settlement agreed
18th Nov 20257:07 amRNSPreliminary Results
13th Nov 20257:00 amRNSNotice of Results
4th Nov 20257:06 amRNSExtension of Joint Development Agreement
15th Oct 20257:00 amRNS-RAwarding of Government Grant
30th Sep 20254:30 pmRNSTotal Voting Rights and Share Capital
8th Sep 20257:00 amRNSIssue of Equity and Director/PDMR Shareholdings
19th Aug 20257:00 amRNSFull Year Trading Update & Director Retirement
9th Jun 20257:00 amRNSBLOCKLISTING SIX-MONTHLY RETURN
28th Apr 202510:48 amRNSJoint Development Agreement
25th Apr 20257:00 amRNSPatent infringement lawsuit against LG
17th Apr 20253:54 pmRNSHigh Court Confirmation of Capital Reduction
15th Apr 20257:00 amRNSInterim Results & Investor Presentation
13th Mar 20257:00 amRNSNotice of Results
21st Jan 20252:20 pmRNSAnnual General Meeting – Voting Results
18th Dec 20248:26 amRNSDirector/PDMR Shareholding
13th Dec 20241:23 pmRNSResult of General Meeting
9th Dec 20247:00 amRNSBlock Listing Six Monthly Return
6th Dec 20246:30 pmRNSNotice of AGM
29th Nov 20247:00 amRNSGlass Lewis and ISS recommendations
28th Nov 20243:23 pmRNSDirector/PDMR Shareholding
28th Nov 20241:25 pmRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNS2024 Annual Report
20th Nov 20247:00 amRNSPreliminary Results
15th Nov 202411:00 amRNSPosting of Circular and Notice of General Meeting
30th Oct 20247:01 amRNSCompletion of Buyback Programme
30th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Oct 20247:00 amRNSReceipt of General Meeting Requisition Notice
23rd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Oct 20247:00 amRNSAppointment of CEO and Notice of Results
22nd Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
21st Oct 20247:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.